Amarantus BioScience, University of Miami deal

The university's Bascom Palmer Eye Institute granted Amarantus an exclusive option to acquire method of use IP covering the use of the mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET) family of proteins to treat retinal diseases, including age-related macular degeneration (AMD), and glaucoma. Amarantus owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications. The company could not be reached for details. ...